NNVC Nanoviricides Inc

Price (delayed)

$1.33

Market cap

$15.67M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.81

Enterprise value

$10.42M

NanoViricides, Inc. is a development stage company that is creating special purpose nanomaterials for antiviral therapy. The Company's novel nanoviricideĀ® class of drug candidates are designed to specifically attack enveloped ...

Highlights
NNVC's debt has shrunk by 100% QoQ
NNVC's quick ratio has dropped by 78% year-on-year and by 25% since the previous quarter
The equity has declined by 37% year-on-year and by 4% since the previous quarter

Key stats

What are the main financial stats of NNVC
Market
Shares outstanding
11.78M
Market cap
$15.67M
Enterprise value
$10.42M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
1.25
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$9.31M
EBITDA
-$8.55M
Free cash flow
-$6.2M
Per share
EPS
-$0.81
Free cash flow per share
-$0.53
Book value per share
$1.06
Revenue per share
$0
TBVPS
$1.11
Balance sheet
Total assets
$13.4M
Total liabilities
$951,074
Debt
$0
Equity
$12.45M
Working capital
$4.37M
Liquidity
Debt to equity
0
Current ratio
5.59
Quick ratio
5.52
Net debt/EBITDA
0.61
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-58.2%
Return on equity
-64%
Return on invested capital
-117.8%
Return on capital employed
-74.7%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

NNVC stock price

How has the Nanoviricides stock price performed over time
Intraday
4.72%
1 week
8.13%
1 month
26.67%
1 year
0.75%
YTD
30.39%
QTD
30.39%

Financial performance

How have Nanoviricides's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$9.7M
Net income
-$9.36M
Gross margin
N/A
Net margin
N/A
Nanoviricides's operating income has decreased by 38% YoY and by 3.8% QoQ
NNVC's net income is down by 36% YoY and by 4.1% QoQ

Growth

What is Nanoviricides's growth rate over time

Valuation

What is Nanoviricides stock price valuation
P/E
N/A
P/B
1.25
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has contracted by 35% YoY and by 3.8% from the previous quarter
The equity has declined by 37% year-on-year and by 4% since the previous quarter
The stock's price to book (P/B) is 25% more than its last 4 quarters average of 1.0 but 11% less than its 5-year quarterly average of 1.4

Efficiency

How efficient is Nanoviricides business performance
Nanoviricides's return on equity has shrunk by 107% YoY and by 17% QoQ
NNVC's return on assets has dropped by 92% year-on-year and by 15% since the previous quarter
Nanoviricides's return on invested capital has decreased by 46% YoY and by 8% QoQ

Dividends

What is NNVC's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for NNVC.

Financial health

How did Nanoviricides financials performed over time
NNVC's total liabilities has soared by 105% YoY but it has shrunk by 61% QoQ
The current ratio has shrunk by 78% YoY and by 26% QoQ
NNVC's debt is 100% lower than its equity
NNVC's debt has shrunk by 100% QoQ
NNVC's debt to equity has dropped by 100% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.